Barkin M, Comisarow R H, Taranger L A, Canada A
J Urol. 1977 Aug;118(2):258-9. doi: 10.1016/s0022-5347(17)57963-x.
Vesical implantation and oral feeding studies in animals raised sufficient suspicion of the carcinogenic propensity of cyclamates to result in their withdrawal from sale throughout the world. The structural similarity to known carcinogens, an effect on human chromosomes in tissue culture and a high carcinogenic potential when combined with non-injurious co-carcinogens gave further support to this ban. On the other hand, numerous epidemiological studies failed to support any statistical relationship between cyclamate ingestion and vesical carcinoma in man. Three patients are described in whom vesical carcinoma developed after a prolonged period of ingestion of an unusually high amount of cyclamate sweetener. Moreover, the severity of the disease appeared to be proportional to the dose ingested. Although this is not a conclusive indictment of the role of cyclamates we believe that patients with bladder cancer should be questioned about intake of cyclamates either directly or in diet soft drinks.
对动物进行的膀胱植入和口服喂养研究引起了人们对甜蜜素致癌倾向的充分怀疑，导致其在全球范围内被停止销售。与已知致癌物的结构相似性、在组织培养中对人类染色体的影响以及与无害助致癌物结合时的高致癌潜力进一步支持了这一禁令。另一方面，大量的流行病学研究未能证实人类摄入甜蜜素与膀胱癌之间存在任何统计学关联。本文描述了三名患者，他们在长期摄入异常大量的甜蜜素甜味剂后患上了膀胱癌。此外，疾病的严重程度似乎与摄入剂量成正比。尽管这并非对甜蜜素作用的确凿指控，但我们认为，对于膀胱癌患者，应直接询问或通过询问其是否饮用含甜蜜素的软饮料来了解他们对甜蜜素的摄入量。
